Ovid Secures $60M in PIPE Financing at $2.01 Per Share
Ovid Therapeutics announced on March 18, 2026, that it secured $60 million in gross proceeds through a private investment in public equity (PIPE) financing. The deal, expected to close around March 19, attracted significant institutional interest, with Point72 leading the round alongside existing investors like Adage Capital Management, Balyasny Asset Management, and RA Capital Management.
Pursuant to the agreement, Ovid is selling 19,154,321 shares of its common stock at a purchase price of $2.01 per share. The financing also includes pre-funded warrants to purchase an additional 10,701,710 shares. While such placements provide crucial growth capital, they can exert downward pressure on a stock's price due to the issuance of new shares.
Positive OV329 Data Spurs Epilepsy Program Expansion
The capital raise directly supports an expansion of Ovid's clinical pipeline, driven by promising new data for its lead drug candidate. The company intends to use the net proceeds to advance the development of OV329, a next-generation GABA-aminotransferase inhibitor, into trials for tuberous sclerosis complex (TSC) and infantile spasms (IS).
This strategic decision follows the announcement of a favorable safety and tolerability profile from a 7 mg dose cohort study of OV329. The results, which showed no treatment-related adverse events, reinforce the drug's potential as a best-in-category treatment for drug-resistant epilepsies and gave the company the confidence to pursue broader indications.
Financing Bolsters Runway as OV4071 Enters Clinic
Ovid's financial position is set to strengthen significantly beyond the PIPE financing. The company also announced that its other drug candidate, OV4071, received clearance to begin Phase 1 trials in Australia. This regulatory milestone triggers a 30-day exercise period for Series A Warrants, which, if fully exercised, could provide up to an additional $53.9 million in gross proceeds by April 17, 2026. Combined with the company's existing cash of $90.4 million as of December 31, 2025, and the new $60 million financing, Ovid is positioning itself with a substantial cash runway to fund multiple clinical programs through 2026 and beyond.
Edgen Stock·Mar 18 2026, 10:37
